Manitty is a French company at the intersection of healthcare and defence. Earlier this year, they were selected to enter Phase 2 of the NATO DIANA Programme, which will provide them with tailored mentorship to accelerate validation and adoption of their flagship innovation, DeepMo.
What does your company do and what is the solution you applied to DIANA with?
"We are Manitty, a health-tech company with a rare expertise in decoding the body’s signals – especially brain activity – and transforming them into actionable insights using advanced AI models.
Our solution, DeepMo, is a dual-use system that continuously monitors vital and neurological signs, detects anomalies, and delivers predictive alerts.
Originally developed for hospitals and transitional care, DeepMo is being adapted for defence to provide real-time health monitoring in the most extreme and high-stress environments, supporting triage and patient regulation from the Point of Injury (PoI) to Role 2 – even when communications are degraded or denied.
We submitted a proposal to DIANA's Human Health & Performance challenge because our solution directly advances resilience, readiness, and survivability for both society and defence."
What problem does your solution solve?
"In mass-casualty, high-tempo operations, first responders and medics must make life-or-death decisions with limited time, limited hands, and limited visibility. Traditional tools aren’t built for the chaos of combat, Anti-Access/Area-Denial (A2/AD) constraints, or intermittent or non-existent comms, and they don’t provide continuous, multimodal insight to prioritise who needs help first.
DeepMo closes this gap. The system is a lightweight, rugged wearable powered by AI that continuously interprets multimodal vitals and captures neurophysiological and autonomic signals to detect deterioration, and autonomously suggest triage codes.
The result: faster, evidence-based triage and better survival during the golden hour, while reducing cognitive load on medics and enabling smarter evacuation and patient regulation."
How did the company get started?
"We began with a simple observation: outside hospitals, continuous, reliable monitoring is missing when it matters most and requires constant human supervision. We built DeepMo to deliver hospital-grade signal quality in the real world – then hardened it for defence: dust, vibration, movement, extreme temperatures, and disrupted networks. As the tech matured, one truth became obvious: the same capability that protects vulnerable patients could also protect soldiers and civilians in harm’s way. Our mission is to bridge medicine and defence with a single, resilient monitoring and triage platform."
Was your company already positioned as a dual-use company before DIANA? Why did you decide to apply to the programme?
"Manitty was first focused on healthcare, but very quickly we identified that DeepMo’s unique capabilities – multimodal monitoring in uncontrolled environments – could make a decisive difference in conflict zones, disaster response, and other austere settings.
The potential for dual-use impact was clear: saving lives both in hospitals and on the battlefield.
We applied to DIANA because it is the world’s leading programme for dual-use innovation. Beyond funding, DIANA offers something truly unique: access to NATO’s test centres, operational exercises, and direct engagement with end users. For us, this ecosystem is the perfect proving ground to validate DeepMo in real-world defence conditions while continuing to strengthen its role in hospitals and civilian care."
How does your tech differ from competitors?
"DeepMo is unique because it is human-centric and dual-use by design. Unlike many innovations that focus on infrastructure or defence hardware, DeepMo puts people’s health at the centre. It integrates multimodal data – heart rate, respiration, movement, and even brain activity – and applies AI to deliver predictive alerts that support timely interventions.
We don’t stop at basic vitals; we decode brain signals (EEG) alongside autonomic markers to detect deterioration that visual inspection can miss in chaotic scenes.
What truly sets DeepMo apart is its balance of precision and portability. Soldiers already carry heavy equipment, so we designed DeepMo as a lightweight, wearable system that consolidates advanced multi-channel data collection into a compact, user-friendly form factor. Despite its small size, it delivers hospital-grade physiological monitoring in extreme conditions, from hospitals and home care to the battlefield.
Finally, DeepMo delivers continuous monitoring and end-to-end support along the chain of care, from the point of injury to Role 2. It can track multiple patients at once and automatically generate structured physiological reports to speed up treatment decisions at each handover.
This fusion of advanced capability, portability, and reliability ensures that critical health insights are always accessible – without adding burden to the user. By bridging hospital-grade care with battlefield resilience, DeepMo represents a powerful step forward in protecting both patients and soldiers."
What has been your biggest success or milestone to date since starting the DIANA programme? How did participation in DIANA’s programme help make this possible?
"Since joining DIANA, one of our key milestones has been securing government contracts to monitor personnel in extreme environments and under high strain, expanding DeepMo’s applications beyond purely medical use cases. These engagements are already demonstrating the real-world value of DeepMo outside the lab.
Equally important has been the direct exchanges with military personnel and medics, which gave us unique insight into operational realities – from the chaos of mass-casualty incidents to the constraints of A2/AD environments. Their feedback has shaped our use cases and confirmed that DeepMo addresses critical gaps in triage and continuous monitoring along the chain of care."
What is next on the horizon for your company or is there another milestone in the future you are excited about?
"Our biggest milestone is still ahead: the deployment of DeepMo in real battle-like conditions during NATO-led exercises and operational environments. This will be the ultimate demonstration of its ability to save lives, support medics, and strengthen resilience under the toughest circumstances.
The next step is to validate DeepMo in upcoming NATO operational exercises, proving its reliability in complex, real-world defence scenarios. In parallel, we are expanding partnerships across NATO’s innovation ecosystem to accelerate adoption and integration into the wider chain of care.
Beyond defence, our ambition is equally strong: to broaden DeepMo’s reach into civilian healthcare, ensuring that the same technology protecting soldiers in combat can also improve patient outcomes in hospitals, emergency response, and disaster relief worldwide."